Invex Therapeutics (ASX:IXC) Total Long-Term Assets: A$0.00 Mil (As of Dec. 2025)


What is Invex Therapeutics Total Long-Term Assets?

Invex Therapeutics ASX:IXC Total Long-Term Assets is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Invex Therapeutics's Total Long-Term Assets for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Total Long-Term Assets Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Long-Term Assets
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Total Long-Term Assets of A$0.00 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Total Long-Term Assets too high?
Invex Therapeutics' current Total Long-Term Assets is A$0.00 Mil.
How does Invex Therapeutics' Total Long-Term Assets compare to VRTX and REGN?
Invex Therapeutics' Total Long-Term Assets of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Total Long-Term Assets is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Total Long-Term Assets of A$0.00 Mil. The current Total Long-Term Assets is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Total Long-Term Assets is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.